京津肺癌协作组于今年2月15日在北京举行了第二届年会。会议交流的重点是小细胞肺癌化疗放疗后的手术问题。北京市胸部肿瘤研究所徐嘉璋介绍了“CE或CEA化疗方案治疗小细胞肺癌”、“长春新碱治疗小细胞肺癌”和“小细胞肺癌外科和综合治疗远期疗效分析”等。该院1957年到1985年241例小细胞肺癌,总5年存活率为23.2%,单纯手术为4.5%,手术加放、化疗的综合治疗为40.8%。医科院肿瘤医院张汝刚介绍小细胞肺癌外科治疗为主的综合治疗104例,切除率为84.6%,总5年存活率为27.5%。术后加化疗1年74.3%,3年37.5%,5年32.4%存 The Beijing-Tianjin Lung Cancer Collaboration Group held its second annual meeting in Beijing on February 15 this year. The focus of the meeting was on surgical problems after chemotherapy and radiotherapy for small cell lung cancer. Xu Jialu from the Beijing Institute of Thoracic Tumors introduced the “CE or CEA chemotherapy regimen in the treatment of small cell lung cancer,” “Vinocricetine treatment of small cell lung cancer,” and “Surgery and comprehensive treatment of small cell lung cancer long-term efficacy analysis.” From 1957 to 1985 in the hospital, 241 cases of small cell lung cancer, the total 5-year survival rate was 23.2%, 4.5% for surgery alone, surgery combined with radiotherapy and chemotherapy for 40.8%. Zhang Jigang, the Cancer Hospital of the Chinese Academy of Medical Sciences, introduced 104 cases of comprehensive treatment for the treatment of small cell lung cancer, with a resection rate of 84.6% and a total 5-year survival rate of 27.5%. Postoperative chemotherapy plus 74.3% for one year, 37.5% for three years, and 32.4% for five years